At onset mitochondrial disorders (MID) frequently manifest as a mono-organic problem but turn into multisystem disease during the disease course in most of the cases. Organs/tissues most frequently affected in MID are the cerebrum, peripheral nerves, and the skeletal muscle. Additionally, most of the inner organs may be affected alone or in combination. Hematological manifestations of MID include aplastic, megaloblastic, or sideroblastic anemia, leukopenia, neutropenia, thrombocytopenia, or pancytopenia. In single cases either permanent or recurrent eosinophilia has been observed. Hematological abnormalities may occur together with syndromic or nonsyndromic MIDs. Syndromic MIDs, in which hematological manifestations predominate, are the Pearson syndrome (pancytopenia), Kearns-Sayre syndrome (anemia), Barth syndrome (neutropenia), and the autosomal recessive mitochondrial myopathy, lactic acidosis and sideroblastic anemia syndrome. In single cases with Leigh’s syndrome, MERRF (myoclonic epilepsy and ragged-red fiber) syndrome, Leber’s hereditary optic neuropathy, and Friedreich’s ataxia anemia has been described. Anemia, leukopenia, thrombocytopenia, eosinophilia, or pancytopenia can frequently also be found in nonsyndromic MIDs with or without involvement of other tissues. Therapy of blood cell involvement in MID comprises application of antioxidants, vitamins, iron, bone marrow-stimulating factors, or substitution of cells.

Keywords:
Bone marrow, Disease, multisystem, Encephalomyopathy, Mitochondrial cytopathy, Mitochondriopathy, Oxidative phosphorylation, Respiratory chain
1.
Zeviani M, Di Donato S: Mitochondrial disorders. Brain 2004;127:2153–2172.
2.
Tarnopolsky MA, Raha S: Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc 2005;37:2086–2093.
3.
Zeviani M, Spinazzola A, Carelli V: Nuclear genes in mitochondrial disorders. Curr Opin Genet Dev 2003;13:262–270.
4.
Zeviani M, Carelli V: Mitochondrial disorders. Curr Opin Neurol 2003;16:585–594.
5.
Bindoff LA: Disorders caused by mitochondrial DNA instability. Eur J Neurol 2004;11(suppl 2):5.
6.
Riggs JE, Schochet SS Jr, Fakadej AV, Papadimitriou A, DiMauro S, Crosby TW, Gutmann L, Moxley RT: Mitochondrial encephalomyopathy with decreased succinate-cytochrome c reductase activity. Neurology 1984;34:48–53.
7.
Limongelli A, Schaefer J, Jackson S, Invernizzi F, Kirino Y, Suzuki T, Reichmann H, Zeviani M: Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet 2004;41:342–349.
8.
Leonard JV, Schapira AHV: Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 2000;355:299–304.
9.
Fontenay M, Cathelin S, Amiot M, Gyan E, Solary E: Mitochondria in hematopoiesis and hematologic diseases. Oncogene 2006;25:4757–4767.
10.
Fleming MD, Campagna DR, Haslett JN, Trenor CC 3rd, Andrews NC: A mutation in a mitochondrial transmembrane protein is responsible for the pleiotropic hematological and skeletal phenotype of flexed-tail (f/f) mice. Genes Dev 2001;15:652–657.
11.
Inoue SI, Yokota M, Nakada K, Miyoshi H, Hayashi JI: Pathogenic mitochondrial DNA-induced respiration defects in hematopoietic cells result in anemia by suppressing erythroid differentiation. FEBS Lett 2007;581:1910–1916.
12.
Bader-Meunier B, Mielot F, Breton-Gorius J, Cramer E, Guichard J, Landrieu P, Dommergues JP, Tchernia G: Hematologic involvement in mitochondrial cytopathies in childhood: a retrospective study of bone marrow smears. Pediatr Res 1999;46:158–162.
13.
Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, Thorburn DR: Diagnostic criteria for respiratory chain disorders in adults and children. Neurology 2002;59:1406–1411.
14.
Gillis L, Kaye E: Diagnosis and management of mitochondrial diseases. Pediatr Clin North Am 2002;49:203–219.
15.
Chinnery PF, Turnbull DM: Clinical features, investigation, and management of patients with defects of mitochondrial DNA. J Neurol Neurosurg Psychiatry 1997;63:559–563.
16.
Fadic R, Johns DR: Clinical spectrum of mitochondrial diseases. Semin Neurol 1996;16:11–22.
17.
McFarland R, Taylor RW, Turnbull DM: The neurology of mitochondrial DNA disease. Lancet Neurol 2002;i:343–351.
18.
Knerr I, Metzler M, Niemeyer CM, Holter W, Gerecke A, Baumann I, Trollmann R, Repp R: Hematologic features and clinical course of an infant with Pearson syndrome caused by a novel deletion of mitochondrial DNA. J Pediatr Hematol Oncol 2003;25:948–951.
19.
Rotig A, Cormier V, Blanche S, Bonnefont JP, Ledeist F, Romero N, Schmitz J, Rustin P, Fischer A, Saudubray JM: Pearson’s marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest 1990;86:1601–1608.
20.
Majander A, Suomalainen A, Vettenranta K, Sariola H, Perkkio M, Holmberg C, Pihko H: Congenital hypoplastic anemia, diabetes, and severe renal tubular dysfunction associated with a mitochondrial DNA deletion. Pediatr Res 1991;30:327–330.
21.
Muraki K, Nishimura S, Goto Y, Nonaka I, Sakura N, Ueda K: The association between haematological manifestation and mtDNA deletions in Pearson syndrome. J Inherit Metab Dis 1997;20:697–703.
22.
Morikawa Y, Matsuura N, Kakudo K, Higuchi R, Koike M, Kobayashi Y: Pearson’s marrow/pancreas syndrome: a histological and genetic study. Virchows Arch A Pathol Anat Histopathol 1993;423:227–231.
23.
Simonsz HJ, Barlocher K, Rotig A: Kearns-Sayre’s syndrome developing in a boy who survived Pearson’s syndrome caused by mitochondrial DNA deletion. Doc Ophthalmol 1992;82:73–79.
24.
Casademont J, Barrientos A, Cardellach F, Rotig A, Grau JM, Montoya J, Beltran B, Cervantes F, Rozman C, Estivill X: Multiple deletions of mtDNA in two brothers with sideroblastic anemia and mitochondrial myopathy and in their asymptomatic mother. Hum Mol Genet 1994;3:1945–1949.
25.
McShane MA, Hammans SR, Sweeney M, Holt IJ, Beattie TJ, Brett EM, Harding AE: Pearson syndrome and mitochondrial encephalomyopathy in a patient with a deletion of mtDNA. Am J Hum Genet 1991;48:39–42.
26.
Mohri I, Taniike M, Fujimura H, Matsuoka T, Inui K, Nagai T, Okada S: A case of Kearns-Sayre syndrome showing a constant proportion of deleted mitochondrial DNA in blood cells during 6 years of follow-up. J Neurol Sci 1998;158:106–109.
27.
Schapira AHV, Cock HR: Mitochondrial myopathies and encephalomyopathies. Eur J Clin Invest 1999;29:886–898.
28.
Nelson I, Bonne G, Degoul F, Marsac C, Ponsot G, Lestienne P: Kearns-Sayre syndrome with sideroblastic anemia: molecular investigations. Neuropediatrics 1992;23:199–205.
29.
Bernes SM, Bacino C, Prezant TR, Pearson MA, Wood TS, Fournier P, Fischel-Ghodsian N: Identical mitochondrial DNA deletion in mother with progressive external ophthalmoplegia and son with Pearson marrow-pancreas syndrome. J Pediatr 1993;123:598–602.
30.
Kearns TP, Sayre GP: Retinitis pigmentosa, external ophthalmoplegia and complete heart block. Ophthalmology 1958;60:280–289.
31.
Servidei S: Mitochondrial encephalomyopathies: gene mutation. Neuromuscul Disord 2004;14:107–116.
32.
Carod-Artal FJ, Lopez Gallardo E, Solano A, Dahmani Y, Herrero MD, Montoya J: Mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurologia 2006;21:357–364.
33.
Leung TF, Hui J, Shoubridge E, Li CK, Chik KW, Shing MM, Wong GW, Yeung WL, Yuen PM: Aplastic anaemia in association with Kearns-Sayre syndrome. J Inherit Metab Dis 1999;22:86–87.
34.
Fischel-Ghodsian N, Bohlman MC, Prezant TR, Graham JM Jr, Cederbaum SD, Edwards MJ: Deletion in blood mitochondrial DNA in Kearns-Sayre syndrome. Pediatr Res 1992;31:557–560.
35.
Abramowicz MJ, Cochaux P, Cohen LH, Vamos E: Pernicious anaemia and hypoparathyroidism in a patient with Kearns-Sayre syndrome with mitochondrial DNA duplication. J Inherit Metab Dis 1996;19:109–111.
36.
Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, Wanders RJ: X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet 2004;126A:349–354.
37.
Kuijpers TW, Maianski NA, Tool AT, Becker K, Plecko B, Valianpour F, Wanders RJ, Pereira R, Van Hove J, Verhoeven AJ, Roos D, Baas F, Barth PG: Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the absence of apoptosis. Blood 2004;103:3915–3923.
38.
Vreken P, Valianpour F, Nijtmans LG, Grivell LA, Plecko B, Wanders RJ, Barth PG: Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun 2000;279:378–382.
39.
Schlame M, Ren M, Xu Y, Greenberg ML, Haller I: Molecular symmetry in mitochondrial cardiolipins. Chem Phys Lipids 2005;138:38–49.
40.
DiMauro S, Schon EA: Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656–2668.
41.
Scharfe C, Hauschild M, Klopstock T, Janssen AJ, Heidemann PH, Meitinger T, Jaksch M: A novel mutation in the thiamine responsive megaloblastic anaemia gene SLC19A2 in a patient with deficiency of respiratory chain complex I. J Med Genet 2000;37:669–673.
42.
Patton JR, Bykhovskaya Y, Mengesha E, Bertolotto C, Fischel-Ghodsian N: Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem 2005;280:19823– 19828.
43.
Zeharia A, Fischel-Ghodsian N, Casas K, Bykhocskaya Y, Tamari H, Lev D, Mimouni M, Lerman-Sagie T: Mitochondrial myopathy, sideroblastic anemia, and lactic acidosis: an autosomal recessive syndrome in Persian Jews caused by a mutation in the PUS1 gene. J Child Neurol 2005;20:449–452.
44.
Inbal A, Avissar N, Shaklai M, Kuritzky A, Schejter A, Ben-David E, Shanske S, Garty BZ: Myopathy, lactic acidosis, and sideroblastic anemia: a new syndrome. Am J Med Genet 1995;55:372–378.
45.
Blatt J, Katerji A, Barmada M, Wenger SL, Penchansky L: Pancytopenia and vacuolation of marrow precursors associated with necrotizing encephalopathy. Br J Haematol 1994;86:207–209.
46.
Nagashima T, Mori M, Katayama K, Nunomura M, Nishihara H, Hiraga H, Tanaka S, Goto Y, Nagashima K: Adult Leigh syndrome with mitochondrial DNA mutation at 8993. Acta Neuropathol (Berl) 1999;97:416–422.
47.
Wang YL, Choi HK, Aul C, Gattermann N, Heinisch J: The MERRF mutation of mitochondrial DNA in the bone marrow of a patient with acquired idiopathic sideroblastic anemia. Am J Hematol 1999;60:83–84.
48.
Goyal S, Riordan-Eva P, Coakes RL: Late onset of Leber’s hereditary optic neuropathy precipitated by anaemia. Eye 2004;18:1017–1018.
49.
Man PY, Turnbull DM, Chinnery PF: Leber hereditary optic neuropathy. J Med Genet 2002;39:162–169.
50.
Akman CI, Sue CM, Shanske S, Tanji K, Bonilla E, Ojaimi J, Krishna S, Schubert R, DiMauro S: Mitochondrial DNA deletion in a child with megaloblastic anemia and recurrent encephalopathy. J Child Neurol 2004;19:258–261.
51.
Van Hove JL, Shanske S, Ciacci F, Ballinger S, Shoffner JS, Wallace DC, Hanioka T, Folkers K, Bossen EH, Kussin PS: Mitochondrial myopathy with anemia, cardiomyopathy, and lactic acidosis: a distinct late onset mitochondrial disorder. Am J Med Genet 1994;51:114–120.
52.
Samad FU, Engel E, Hartmann RC: Hypoplastic anemia, Friedreich’s ataxia and chromosomal breakage: case report and review of similar disorders. South Med J 1973;66:135–140.
53.
Reichenbach J, Schubert R, Horvath R, Petersen J, Futterer N, Malle E, Stumpf A, Gebhardt BR, Koehl U, Schraven B, Zielen S: Fatal neonatal-onset mitochondrial respiratory chain disease with T cell immunodeficiency. Pediatr Res 2006;60:321–326.
54.
Tulinius MH, Oldfors A, Holme E, Larsson NG, Houshmand M, Fahleson P, Sigstrom L, Kristiansson B: Atypical presentation of multisystem disorders in two girls with mitochondrial DNA deletions. Eur J Pediatr 1995;154:35–42.
55.
Bourgeron T, Chretien D, Poggi-Bach J, Doonan S, Rabier D, Letouze P, Munnich A, Rotig A, Landrieu P, Rustin P: Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J Clin Invest 1994;93:2514–2518.
56.
Fleming MD: The genetics of inherited sideroblastic anemias. Semin Hematol 2002;39:270–281.
57.
Matthes T, Rustin P, Trachsel H, Darbellay R, Costaridou S, Xaidara A, Rideau A, Beris P: Different pathophysiological mechanisms of intramitochondrial iron accumulation in acquired and congenital sideroblastic anemia caused by mitochondrial DNA deletion. Eur J Haematol 2006;77:169–174.
58.
Hellier KD, Hatchwell E, Duncombe AS, Kew J, Hammans SR: X-linked sideroblastic anaemia with ataxia: another mitochondrial disease? J Neurol Neurosurg Psychiatry 2001;70:65–69.
59.
Furuyama K, Harigae H, Heller T, Hamel BC, Minder EI, Shimizu T, Kuribara T, Blijlevens N, Shibahara S, Sassa S: Arg452 substitution of the erythroid-specific 5-aminolaevulinate synthase, a hot spot mutation in X-linked sideroblastic anaemia, does not itself affect enzyme activity. Eur J Haematol 2006;76:33–41.
60.
Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, Koeller DM: Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 1999;8:743–749.
61.
Lill R, Kispal G: Mitochondrial ABC transporters. Res Microbiol 2001;152:331–340.
62.
Maguire A, Hellier K, Hammans S, May A: X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the ABC7 gene predicting V411L. Br J Haematol 2001;115:910–917.
63.
Maassen JA: Mitochondrial diabetes, diabetes and the thiamine-responsive megaloblastic anaemia syndrome and MODY-2. Diseases with common pathophysiology? Panmi- nerva Med 2002;44:295–300.
64.
Ricketts CJ, Minton JA, Samuel J, Ariyawansa I, Wales JK, Lo IF, Barrett TG: Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families. Acta Paediatr 2006;95:99–104.
65.
Ozdemir MA, Akcakus M, Kurtoglu S, Gunes T, Torun YA: TRMA syndrome (thiamine-responsive megaloblastic anemia): a case report and review of the literature. Pediatr Diabetes 2002;3:205–209.
66.
Marriage B, Clandinin MT, Glerum DM: Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc 2003;103:1029–1038.
67.
Heller T, Hochstetter V, Basler M, Borck V: Vitamin B6-sensitive hereditary sideroblastic anemia. Dtsch Med Wochenschr 2004;129:141–144.
68.
Klepper J, Leiendecker B, Riemann E, Baumeister FA: The ketogenic diet in German-speaking countries: update 2003. Klin Pädiatr 2004;216:277–285.
69.
Angelini C, Federico A, Reichmann H, Lombes A, Chinnery P, Turnbull D: Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 2006;13:923–929.
70.
DiMauro S, Hirano M, Schon EA: Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006;34:265–283.
71.
Zaffanello M, Zamboni G: Therapeutic approach in a case of Pearson’s syndrome. Minerva Pediatr 2005;57:143–146.
72.
Vallance HD, Jeven G, Wallace DC, Brown MD: A case of sporadic infantile histiocytoid cardiomyopathy caused by the A8344G (MERRF) mitochondrial DNA mutation. Pediatr Cardiol 2004;25:538–540.
73.
Riess ML, Eells JT, Kevin LG, Camara AK, Henry MM, Stowe DF: Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology 2004;100:498–505.
74.
Riess ML, Kevin LG, McCormick J, Jiang MT, Rhodes SS, Stowe DF: Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in guinea pig isolated hearts. Anesth Analg 2005;100:46–53.
75.
Waldhauser KM, Torok M, Ha HR, Thomet U, Konrad D, Brecht K, Follath F, Krahenbuhl S: Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther 2006;319:1413–1423.
76.
Finsterer J: Mitochondriopathies. Eur J Neurol 2004;11:163–186.
77.
Wei YH, Lin TN, Hong CY, Chiang BN: Inhibition of the mitochondrial Mg2+-ATPase by propranolol. Biochem Pharmacol 1985;34:911–917.
78.
Kubat K: Lactate acidosis: a rare or common disease? Vnitr Lek 1995;41:320–324.
79.
Walker UA: Mitochondrial medicine for internists. Med Klin (Munich) 2000;95:689–696.
80.
Cocco T, Cutecchia G, Montedoro G, Lorusso M: The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase. J Bioenerg Biomembr 2002;34:251–258.
81.
McIntosh LJ, Hong KE, Sapolsky RM: Glucocorticoids may alter antioxidant enzyme capacity in the brain: baseline studies. Brain Res 1998;791:209–214.
82.
Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, Hidaka T, Toshima H: A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 1993;195:945–951.
83.
Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Waldhausl W, Furnsinn C: Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 2004;311:109–114.
84.
Fromenty B, Pessayre D: Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995;67:101–154.
85.
Lewis JA, Huq A, Najarro P: Inhibition of mitochondrial function by interferon. J Biol Chem 1996;271:13184–13190.
86.
Finsterer J, Haberler C, Schmiedel J: Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol 2005;28:148–149.
87.
Sztark F, Payen JF, Piriou V, Rigoulet M, Ventura-Clapier R, Mazat JP, Leverve X, Janvier G: Cellular energy metabolism: physiologic and pathologic aspects. Ann Fr Anesth Reanim 1999;18:261–269.
88.
Jackson-Lewis V, Przedborski S: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 1994;35:244–245.
89.
Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, Raynaud E, Lacampagne A: Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun 2005;338:1426–1434.
90.
Silva MF, Ruiter JP, Illst L, Jakobs C, Duran M, de Almeida IT, Wanders RJ: Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis 1997;20:397–400.
91.
Walker UA: Inherited and acquired disorders of mitochondrial DNA. Schweiz Rundsch Med Prax 2002;91:2129–2138.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.